On September 24, the 21st China-ASEAN Expo and the China-ASEAN Business and Investment Summit officially opened. During the event, the 2024 Nanning Investment and Trade Fair and Major Project Signing Ceremony were held. Li Jing, CEO of Fosun Pharma and Chief Executive Officer of the Mature Products and Manufacturing Business Unit, represented Fosun Pharma at the signing ceremony. They signed a strategic cooperation framework agreement with Guangxi Wuzhou Zhongheng Group Co., Ltd. and Nanning Production Investment Unified Investment Management Co., Ltd. According to the agreement, the three parties will jointly invest in establishing a platform company. The main business will focus on exporting mature pharmaceutical products to ASEAN countries. They will develop differentiated product strategies for different countries, including the selection of drugs, cooperation models with local pharmaceutical companies, and enhance local operations in ASEAN countries. The main products include biologics, vaccines, first generics, key active pharmaceutical ingredients, chemical medicines, traditional chinese medicine, chinese patent medicine, and formulated granules.
复星医药与中恒集团、南宁产投签署战略合作框架协议 拟布局东盟医药市场
Fosun Pharma signed a strategic cooperation framework agreement with Guangxi Wuzhou Zhongheng Group and Nanning Production Investment to lay out the ASEAN pharmaceutical market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.